
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is positioned favorably due to the promising clinical performance of stenoparib, which has demonstrated durable benefits and a median overall survival exceeding 25 months in its Phase 2 trial for advanced recurrent ovarian cancer. The company's innovative Drug Response Predictor (DRP) technology enhances patient targeting, potentially leading to improved clinical outcomes and a more efficient drug development process. Additionally, the current valuation reflects a significant upside potential based on net present value (NPV) analyses, indicating a balanced risk-reward scenario for investors.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which, while better than some estimates, highlights ongoing financial strain and may indicate limited near-term profitability. The company continues to face significant risks including balance sheet and liquidity challenges, potential failures in clinical trials, and the uncertain ability to gain or maintain necessary regulatory approvals for its products. Additionally, external factors such as competitive pressures, shifting investor sentiment, and evolving healthcare priorities further exacerbate the negative outlook for Allarity Therapeutics's stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares